Abstract | The congenital myopathies are a group of early-onset, non-dystrophic neuromuscular conditions with characteristic muscle biopsy findings, variable severity and a stable or slowly progressive course. Pronounced weakness in axial and proximal muscle groups is a common feature, and involvement of extraocular, cardiorespiratory and/or distal muscles can implicate specific genetic defects. Central core disease (CCD), multi-minicore disease (MmD), centronuclear myopathy (CNM) and nemaline myopathy were among the first congenital myopathies to be reported, and they still represent the main diagnostic categories. However, these entities seem to belong to a much wider phenotypic spectrum. To date, congenital myopathies have been attributed to mutations in over 20 genes, which encode proteins implicated in skeletal muscle Ca 2+ homeostasis, excitation-contraction coupling, thin-thick filament assembly and interactions, and other mechanisms. RYR1 mutations are the most frequent genetic cause, and CCD and MmD are the most common subgroups. Next-generation sequencing has vastly improved mutation detection and has enabled the identification of novel genetic backgrounds. At present, management of congenital myopathies is largely supportive, although new therapeutic approaches are reaching the clinical trial stage.
The congenital myopathies are a genetically hetero geneous group of earlyonset neuromuscular disorders characterized by variable degrees of muscle weakness and distinctive structural abnormalities in muscle biopsy samples. The conditions that have been identified to date are mostly disorders of muscle excitation-contraction coupling (ECC) or of proteins primarily involved in sarcomeric filament assembly and interaction. However, recent findings suggest other less common pathogenic mechanisms. The concept of congenital myopathies was established in the 1950s and 1960s, when the application of histochemical and ultrastructural techniques to dis eased muscle identified histopathological features that were considered to be pathognomonic. Recognition of these features -namely, central cores, multiminicores, central nuclei and nemaline rods -resulted in the desig nation of four novel disease entities, central core disease (CCD) 1 , multiminicore disease (MmD) 2 , centronuclear myopathy (CNM) 3 and nemaline myopathy 4 , which still represent the main diagnostic categories.
Considerable progress has been made in under standing the phenotypic spectrum, diagnosis and management of the congenital myopathies. In addition to primary myopathic features, nonneuromuscular mani festations are observed in several forms, point ing to a role for the defective proteins in nonskeletal muscle tissues 5 . Muscle imaging, in particular, muscle MRI, has emerged as a powerful tool for deep pheno typing 6 . Presentations late in adulthood have now been recognized 7, 8 , and owing to improved standards of care, even patients with severe earlyonset forms increasingly transition from paediatric to adult neurology services.
Since the identification of dominant mutations in the skeletal muscle ryanodine receptor 1 (RYR1) gene as the cause of malignant hyperthermia in 1991 and CCD in 1993 9, 10 , mutations in more than 20 genes have been identified in patients with congenital myopathies. Introduction of nextgeneration sequencing (NGS) techniques into routine clinical diagnosis 11 has resulted in an improved detection rate for mutations in genes such as RYR1, nebulin (NEB) and titin (TTN). Owing to their large size, these genes were previously only stud ied by Sanger sequencing in a few patients. Novel NGS techniques have led to the recognition that different mutations in the same gene can give rise to various histo pathological phenotypes, and that mutations in different genes can cause the same histopathological feature, often owing to functional associations between the defective proteins. Moreover, it has become increasingly clear that many congenital myopathies are characterized by non specific or complex pathological abnormalities rather than a 'pure' muscle pathology picture. A classification based on predominant histopathological and associated clinical features is still useful; however, it is also help ful to consider these conditions according to the main underlying disease mechanisms.
In this Review, we summarize genetic, clinical and pathological features of the main congenital myopathies. Common pathogenic mechanisms, diagnostic and cur rent management approaches, and principles of therapy development will be outlined.
Classification and epidemiology
Data concerning the precise epidemiology of the con genital myopathies are limited and are mostly focused on the four main pathological variants: CCD, MmD, CNM and nemaline myopathy. The key characteristics of these entities are detailed below and illustrated in FIG. 1.
CCD -initially described in the 1950s 1 -and MmD 2 are often referred to as the 'core myopathies' 12 , and their names are derived from the histochemical appearance of focally reduced oxidative enzyme activ ity, which corresponds to myofibrillar changes on ultrastructural examination. CCD is characterized by centrally located, welldemarcated cores that run along the fibre axis for a substantial distance on longitudinal sections, whereas MmD is defined by multiple cores of less welldefined appearance and morelimited length.
The hallmark of CNM is the presence of fibres with centralized nuclei, which show variations in terms of numbers and associated features between muscles and genetic backgrounds. Nemaline myopathy is character ized by the presence of numerous nemaline rods that stain red with Gomori trichrome and can be confirmed by electron microscopy 13 . The overall prevalence of these congenital myopathy variants has been estimated at 1 in 26,000 14 . Nemaline myopathy was originally considered to be the most fre quent form, but emerging data suggest that congenital myopathies with cores (CCD and MmD) represent the most common subgroup. Marked genetic heterogeneity is now acknowledged, as detailed below. RYR1 seems to be the gene most frequently involved in congenital myo pathies, in particular, CCD and MmD. Recessive NEB mutations and de novo dominant mutations in ACTA1, which encodes skeletal muscle αactin, are the most common known causes of nemaline myopathy, whereas Xlinked recessive mutations in the myotubularin gene (MTM1) are believed to be the most common cause of CNM. Mutations in TTN are increasingly recognized and may be involved in a substantial proportion of currently unresolved congenital myopathies as well as other neuro muscular disorders, including muscular dystrophies 15 . The genes implicated in the congenital myo pathies are listed in 
Clinicopathology and genetics

Congenital myopathies with cores
In view of their pathological and genetic overlap, CCD, MmD and malignant hyperthermia are discussed together in this section.
CCD is closely associated with dominant RYR1 mutations, whereas MmD is genetically more hetero geneous. Most cases of MmD have been attributed to recessive mutations in RYR1 [16] [17] [18] , SEPN1 (also known as SELENON) 19 or -less frequently -MYH7 20 . Histopathological features consistent with MmD have also been described in some patients with recessive mutations in MEGF10, which encodes multiple epider mal growth factorlike domains protein 10 [21] [22] [23] [24] . Cores or minicores in muscle biopsy samples can also be promi nent in TTNrelated myopathies 25 , often in conjunction with other myopathic and dystrophic features, and might occur in other neuromuscular disorders.
Clinically, CCD due to dominant RYR1 mutations 12 is usually a mild condition, although early severe pres entations, often associated with de novo inheritance, have been recorded 26 . Extraocular muscles are usually spared, and facial, bulbar and respiratory involvement is typically mild. Congenital dislocation of the hips and scoliosis are common. Most patients achieve independent ambulation and have a static or only slowly progressive course.
• Congenital myopathies are clinically and genetically heterogeneous conditions characterized by muscle weakness and distinctive structural abnormalities in muscle biopsy samples • Clinically, congenital myopathies have a stable or slowly progressive course, and the severity varies depending on the causative mutation • More than 20 genes have been implicated in congenital myopathies • The most commonly affected genes encode proteins involved in skeletal muscle Ca 2+ homeostasis, excitation-contraction coupling and thin-thick filament assembly and interactions • Management of congenital myopathies is largely supportive, although experimental therapeutic approaches are reaching the clinical trial stage
The clinical features of MmD are more variable 12 . SEPN1related myopathies 19, 27 are characterized by marked weakness, early spinal rigidity, scoliosis and res piratory impairment. Patients with recessively inherited RYR1related core myopathies exhibit a distribution of weakness and wasting that resembles the SEPN1related form but have additional extraocular muscle involve ment and, with few exceptions, lack severe respiratory impairment 17, 18 . Various combinations of scoliosis, spinal rigidity, multiple (mainly distal) contractures and associ ated cardiomyopathy can occur in TTNrelated and MYH7-related forms 20, 25 . MEGF10related myopathies have a wide clinical spectrum, ranging from a severe earlyonset myopathy with areflexia, respiratory dis tress and dysphagia (termed EMARDD) 21, 23, 24 to adult onset cases with minicores in muscle biopsy samples 22 . Muscle MRI can help to differentiate genetically distinct core myopathies 28, 29 . Dominant RYR1related CCD is allelic to the malig nant hyperthermia susceptibility (MHS) trait -a pharmaco genetic predisposition to malignant hyperther mia and severe adverse reactions to volatile anaesthetics and muscle relaxants 30 -and some CCDassociated RYR1 mutations also carry an increased risk of MHS. The association between MHS and recessive RYR1related MmD is less well established; however, some cases of MmD have been attributed to compound hetero zygosity for dominant MHSassociated RYR1 muta tions and missense, nonsense or other lossoffunction mutations 18, 31, 32 . RYR1related King-Denborough syndrome (KDS) is an MHSassociated myopathy characterized by dys morphic facial features, short stature, spinal rigid ity, scoli osis and various histopathological features 33 . Another recently recognized myopathy with similar clinico pathological features is Native American myo pathy (NAM), originally described in the Lumbee popu lation of North Dakota and caused by homozygosity for a founder mutation (Trp284Ser) in STAC3, which encodes SH3 and cysteinerich domaincontaining protein 3 34 . MHSassociated RYR1 mutations have also been identified as a common cause of exertional myalgia and rhabdomyolysis (ERM) in otherwise healthy individu als with various muscle biopsy findings 35 . Of note, exer tional myalgia can be prominent in CCD 36 , and mild to moderate creatine kinase elevations (up to 1,000 inter national units (IU)/l), which are unusual in the context of other congenital myopathies, are not uncommon. MHSassociated RYR1 mutations can also give rise to lateonset axial myopathy in previously healthy (or even athletic) individuals 37, 38 .
Centronuclear myopathy CNM 39 is associated with Xlinked recessive mutations in the myotubularin gene MTM1 (a condition termed Xlinked myotubular myopathy or XLMTM) 40 , auto somal dominant mutations in dynamin 2 (DNM2) 41 and amphiphysin II (BIN1) 42 , and autosomal recessive mutations in RYR1 43 , BIN1 44 and TTN
45
. Recessive muta tions in SPEG have been identified in a small number of families 46 , and dominant mutations in CCDC78 47 were found in one isolated pedigree. Heterozygous missense variants in MTMR14, which have been identified in two patients with CNM, might represent a genetic modifier of other genetic backgrounds 48 . In MTM1related CNM, the central nuclei are usu ally spaced out along the long fibre axis, whereas in DNM2related cases, these nuclei can form chains. In the rare BIN1related cases, the central nuclei can form clusters. In patients with MTM1related CNM, typical features of the muscle fibres include central areas of increased oxidative enzyme activity and a pale peripheral halo. These features, along with the presence of central nuclei, are also seen in congenital myotonic dystrophy. Strictly centralized nuclei are more common than multiple internalized nuclei in the MTM1-related, DNM2related and BIN1related forms of CNM 40, 41, 44 , whereas multiple internalized nuclei are more common in RYR1related and TTNrelated cases 43 . A radial distri bution of sarcoplasmic strands that stain positively with NADH tetrazolium reductase and periodic acid-Schiff is often seen in DNM2related CNM 41 . 'Necklace' fibres are often seen in patients carrying milder MTM1 muta tions or in female carriers of MTM1 mutations 49 , and occasionally in patients carrying DNM2 mutations 50 . Ultrastructural triad abnormalities are observed in most forms of CNM 51 . From a clinical perspective, extraocular muscle involvement is a consistent feature of most forms of CNM 52 , the exceptions being the TTNrelated, SPEG related and CCDC78related forms. The most severe form, XLMTM, typically manifests in affected males with profound hypotonia, weakness and contractures at birth, as well as bulbar and respiratory involvement that almost always necessitates ventilation for survival. Although the provision of constant respiratory support improves life expectancy in patients with XLMTM, some longterm survivors experience complica tions 53 , probably related to the ubiquitous role of the defective protein.
Dominantly inherited CNM associated with muta tions in DNM2 is frequently a relatively mild condi tion 41, 54 , although moresevere de novo cases have been recorded 55, 56 
75
. The number and distribution of nemaline rods vary among muscles and patients. Rods are believed to be derived from Zlines and may show continuity with these structures. The rods are mainly cytoplasmic but can also be nuclear, particularly in ACTA1related Nature Reviews | Neurology , where additional actin accumu lation and compensatory expression of cardiac actin can be observed. Nemaline rods are usually seen in both type I and type II muscle fibres, except in patients with TPM3 mutations, where they are limited to type I fibres. Numerous small rectangular rods in fibres with sparse myofibrils are a feature of KLHL40related nemaline myopathy 70 . Clinically, nemaline myopathy is highly variable and is conventionally classified by age of onset and sever ity. Severe, often lethal cases within the fetal akinesia spectrum have been reported in association with reces sive mutations in KLHL40 70 , KLHL41 71 , LMOD3 72 and MYO18B
, whereas the typical congenital form charac terized by infantile onset, hypotonia and often dispro portionate bulbar involvement is most commonly due to recessive NEB mutations 77 . Dominant -frequently de novo -ACTA1 mutations are often associated with severe congenital presentations, but milder cases have been reported 65, [78] [79] [80] . KBTBD13related nemaline myo pathy is an unusual form characterized by progressive proximal and neck weakness, gait abnormalities, poor exercise tolerance and peculiar slowness of movement 81 . Extraocular muscle involvement is seen in only a frac tion of patients with KLHL40, KLHL41 and LMOD3 mutations. Cardiomyopathy is sometimes seen in MYPNassociated and MYO18Bassociated nemaline myopathy 74, 75 . Marked distal involvement is observed in numerous forms of nemaline myopathy, and many of the causative genes have also been implicated in dis tinct distal arthrogryposis syndromes 82 . Muscle MRI might help to distinguish different genetic forms of nemaline myopathy 83 .
Other congenital myopathies
In recent years, we have witnessed an expansion of the phenotypic spectrum associated with the known congenital myopathyassociated genes, as well as the description of novel conditions that share some of the clinical and muscle biopsy findings of the better characterized entities without reaching a comparable level of histopathological 'purity' . These congenital myopathies with nonspecific, multiple (structural) and unusual or other features are summarized in the sections that follow.
Congenital myopathies with nonspecific features.
Marked type I fibre predominance or uniformity is com mon in all congenital myopathies and can be the sole presenting feature 84 . Type I predominance and atrophy were also reported in one consanguineous family with clinical features of a congenital myopathy and reces sive mutations in 3hydroxyacylCoA dehydratase 1 (HACD1) 85 . Recessive mutations in the corresponding canine gene cause a form of CNM in dogs 86, 87 , although increased numbers of central nuclei are not a feature in humans with HACD1 mutations. Congenital fibre type disproportion, in which type I fibres are substantially smaller than type II fibres, is another common feature that has been reported in association with mutations in TPM3 88, 89 , RYR1 90 , ACTA1 91 , SEPN1 92 and MYH7
93
, with or without additional structural abnormalities.
Congenital myopathies with multiple structural abnormalities. Congenital myopathies with multiple structural abnormalities, which were already recognized in the premolecular era 94 , have now been largely genetically resolved and are often attributed to previously identi fied genetic backgrounds. The common occurrence of cores and rods (core-rod myopathy) has been ascribed to mutations in RYR1, ACTA1 and NEB, whereas the com bination of cores and central nuclei is seen with RYR1, TTN, CCDC78, DNM2 and SPEG mutations.
Novel entities that lack a single predominant histo pathological abnormality and, therefore, do not readily fit into the conventional classification are increasingly recognized. CACNA1Srelated myopathy 95 is character ized by marked neonatal hypotonia, generalized weak ness with pronounced axial involvement, and variable extraocular, bulbar and respiratory features. This con dition is caused by recessive and dominant mutations in CACNA1S, which encodes voltagedependent Ltype Ca 2+ channel subunitα1S (Cav1.1), the poreform ing subunit of the voltage sensing Ltype Ca 2+ channel dihydro pyridine receptor (DHPR) in skeletal muscle. Allelic DHPR mutations were previously associated with dominantly inherited forms of periodic paralysis (and, in rare cases, MHS phenotypes) 96, 97 . Characteristic histopathological features of CACNA1Srelated myo pathy include sarcoplasmic reticulum (SR) dilatation, increased numbers of internal nuclei, and myofibrillar disorganization resembling minicores.
Recessively inherited PYROXD1related congenital myopathy 98 is an earlyonset myopathy of moderate severity characterized by slowly progressive generalized Fibre typing is preserved, with a predominance of type I fibres (darker staining), and both type I and type II fibres display foci of diminished or absent oxidative staining (multi-minicores) and, occasionally, larger lesions (parts e,f). Tissues samples from a patient with MTM1-related centronuclear myopathy (CNM) (parts g-i). Samples from a male neonate with severe X-linked recessive myotubular myopathy show many fibres with centrally placed nuclei (part g). Most fibres display pale peripheral haloes (part h), and type I fibres predominate (part i). Tissues samples from an adult with DNM2-related CNM (parts j-l). Muscle shows a marked increase in central nucleation and perimysial fatty infiltration (part j). Many fibres display 'radial strands' emanating from a centrally placed nucleus (part k). Type I fibre predominance and hypotrophy create fibre size disproportion; central nuclei are present in both fibre types (part l). Tissue samples from a severely affected neonate with de novo dominant ACTA1-related nemaline myopathy (parts m-o). Muscle shows myopathic fibre size variation with the appearance of two fibre populations: smaller type I and larger type II fibres (part m). Numerous thread-like inclusions are seen in both fibre sizes and appear red with the modified Gomori trichrome stain (part n) and eosinophilic with haematoxylin and eosin (part m). Pale-stained type I fibres are often more severely affected than type II fibres, showing atrophy or hypotrophy (part o). Muscle biopsy samples were stained with haematoxylin and eosin (parts a,d,g,j,m), NADH tetrazolium reductase (parts b,e,h,k) and modified Gomori trichrome (part n), as well as stains for slow myosin heavy chain (parts c,f,i,l) and myosin ATPase at pH 4.6 (part o). 99, 103 , whereas accumulation of slow myosin (socalled 'hyaline bodies') can be seen in some MYH7related cases. Other features that may be seen in MYH7related and MYH2related myopathies include increased connective tissue, internal nuclei, rimmed vacuoles, and ring and lobulated fibres 20, 93, 99, 103 . In the context of overlapping histopathological fea tures, the presence of extraocular muscle involve ment might cause diagnostic confusion with recessive RYR1related MmD.
◀
Two other conditions combining ocular involve ment, contractures within the distal arthrogryposis spectrum and features of a congenital myopathy are recessively inherited ECEL1related congenital myo pathy [104] [105] [106] [107] [108] and dominantly inherited PIEZO2related congenital myopathy 109 (also classified as distal Genes most commonly implicated in the classic structural congenital myopathies, and the corresponding conditions. arthrogryposis type 5), both of which are associated with cores and increased internal nuclei in muscle biopsy samples.
A recessive congenital myopathy due to homozygous or compound heterozygous mutations in SCN4A, a gene previously associated with dominantly inherited myo tonia and periodic paralysis, was recently described 110 . This condition has a wide clinical spectrum, from severe in utero (often early lethal) presentations to neonatal onset conditions of variable severity. The pheno type is mainly characterized by hypotonia, facial and neck weakness, respiratory and swallowing difficul ties and earlyonset spinal deformities, but interestingly, it is not associated with clinical or electrophysiological evidence of myotonia. Mutations in the same gene are associated with a presentation featuring severe neo natal laryngospasm 111 . Histopathologically, SCN4Arelated congenital myopathy is characterized by a combina tion of increased fibre size heterogeneity and variable increases in fatty tissue and tends to lack moredistinct structural abnormalities 110 . In fact, many of the genetic backgrounds implicated in congenital myopathies -in particular, mutations in RYR1, TTN and DNM2 -are associated with marked increases in fat and connective tissue, mimicking a congenital muscular dystrophy 112, 113 .
Congenital myopathies with unusual or other features.
Some of the genes that are associated with nemaline myopathy -namely, TPM2, TPM3, ACTA1, NEB and MYPN -have also been implicated in rare myopathies with unusual histopathological features, such as cap myopathy and zebra body myopathy 73, [114] [115] [116] . STIM1related and ORAI1related congenital myo pathies 117 caused by dominant gainoffunction mutations result in either tubular aggregate myopathy -a slowly progressive myopathy with varying degrees of extra ocular muscle involvement, exertional myalgia and vari able calf hypertrophy -or York platelet and Stormorken syndromes, related disorders that form a clinical con tinuum and are characterized by congenital myopathy, pupillary and platelet abnormalities and vari able multi system involvement. Recessive inheritance of lossof function mutations in ORAI1 and STIM1 leads to various combinations of severe combined immunodeficiency, ectodermal dysplasia and congenital myopathy, a com bination that was reported in the premolecular era in association with minicores in muscle biopsy samples 118 . 'Triadin knockout syndrome' , which is caused by compound heterozygosity for TRDN null mutations, is a recessive cardiac arrhythmia syndrome with various clinical and histopathological features of a congenital myopathy, the latter features being characterized by focal dilatation and degeneration of the lateral SR cis ternae 119, 120 . The reason for the highly variable pene trance of the myopathy associated with TRDN mutations remains unknown.
Mutations in TRIM32 are associated with limbgirdle muscular dystrophy type 2H and sarcotubular myopathy, and mutations in TRIM54 and TRIM63 are associated with microtubular abnormalities and myosincontaining inclusions 121 . These observations illustrate the increas ingly fluid boundaries between congenital myopathies and other neuromuscular disorders, in particular, myofibrillar, protein aggregate and vacuolar myopathies.
Pathogenesis
The vast majority of the proteins implicated in congenital myopathies have been associated with primary or sec ondary defects of muscle ECC, intracellular Ca 2+ homeo stasis and disturbed sarcomeric assembly and function (FIG. 2) , although other mechanisms are emerging.
ECC, muscle contraction and relaxation
ECC is the process whereby an electrical signal gener ated by a neuronal action potential is converted into a chemical gradient -that is, an increase in myoplasmic Ca 2+ -leading to muscle contraction. The two main players in skeletal muscle ECC are RYR1 and DHPR (FIG. 2) . RYR1 is located on the SR junctional face mem brane, and DHPR is located on the plasmalemma and transverse tubules (Ttubules) -plasmalemmal invagi nations that run deep into the muscle fibre. ECC is extremely rapid, occurring within a few milliseconds, and relies on a highly defined subcellular architecture, with each DHPR positioned opposite an RYR1, and every other RYR1 tetramer facing four DHPRs arranged in a characteristic checkerboard shape called a tetrad.
In addition to its principal regulation through direct interaction with DHPR, RYR1 is regulated by Ca 2+ and Mg 2+ and is subjected to posttranslational modifications such as phosphorylation, sumoylation and nitrosylation, which affect the channel open probability. The junc tional SR membrane contains RYR1 as well as many other smaller proteins, including the structural proteins triadin and junctin (also known as aspartyl/ asparaginyl βhydroxylase), junctional SR protein 1 (JP45), the highcapacity, lowaffinity Ca 2+ binding protein calse questrin 122, 123 (in an area adjacent to RYR1), and other proteins with roles in the fine regulation of SR Ca 2+ release or in maintaining the structural integrity of the Ca 2+ release machinery 122, [124] [125] [126] [127] [128] [129] [130] [131] . Following its release from the SR, Ca 2+ binds to troponin C and interacts directly with thin filaments. As a consequence, muscle contraction occurs in the sarcomere, a structure that is principally composed of parallel thick and thin filaments. Sarcomeric regulation of contraction involves structural changes in the thin filament complex (composed of actin, tropomyosin and troponin), triggered by Ca 2+ binding to troponin. The simplest model for the regulation of the sarcomere by Ca 2+ is based on steric blocking, whereby tropomyosin prevents myosin from binding to the actin filament to generate force. Binding of Ca 2+ to troponin triggers a chain reaction that results in azimuthal movements of tropomyosin around the filament to unmask binding sites on actin for myosin -the molecular motor and also the main component of thick filaments -allowing force production and motion 132 . These contractile pro teins and related isoforms are differently expressed in slowtwitch and fasttwitch muscles to fulfil different functional demands 132 . Termination of the contraction cycle and muscle relaxation is achieved by RYR1 closure and activation of sarcoplasmic/endoplasmic reticulum Ca 2+ ATPase (SERCA), the protein component that is responsible for pumping the Ca 2+ back into the SR 133 . SERCA activity is modulated by two small regulatory proteins, sarcolipin and phospholamaban [134] [135] [136] . Although skeletal muscle ECC can occur in the pres ence of extracellular Ca 2+ in the nanomolar range, a wide consensus exists that Ca 2+ entry from the extracellular space is essential to ensure prolonged muscle activity. Two main mechanisms of Ca 2+ entry have been identi fied in skeletal muscle: excitationcoupled Ca 2+ entry via DHPR, which is activated by a train of action potentials or prolonged membrane depolarization; and storeoperated Ca 2+ entry via stromal interaction molecule 1 (encoded by STIM1) and Ca 2+ releaseactivated Ca 2+ channel protein 1 (ORAI1), which is triggered by depletion of endoplasmic reticulum and SR Ca 2+ stores [137] [138] [139] [140] [141] .
ECC and Ca 2+ homeostasis abnormalities Mutations in RYR1 are the most common cause of pri mary defects of ECC and Ca 2+ homeostasis 7, 18, 142, 143 . Functional studies utilizing cellular and animal models 144, 145 indicate that excessive Ca 2+ release and lower RYR1 activation thresholds are consequences of dominantly inherited MHSassociated RYR1 muta tions, whereas both SR Ca 2+ store depletion with a resulting increase in cytosolic Ca 2+ levels (the 'leaky channel' hypothesis) and disturbed ECC (the 'excitationcontraction uncoupling' hypothesis) have been proposed as mechanisms underlying dominantly inherited CCD 142 . On the basis of the limited studies performed so far, quantitative reduction of RYR1 channels is a more likely mechanism than qualitative RYR1 dysfunction in reces sive RYR1related myopathies [146] [147] [148] . Primary or secondary reductions in Cav1.1 protein levels are seen in recessive RYR1related and CACNA1Srelated congenital myo pathies 95, 146 ; the latter conditions also feature disturbed ECC and, consequently, reduced depolarization induced SR Ca 2+ release in myotubes and mature muscle fibres. STAC3, the gene that is homozygously mutated in NAM, encodes a protein that targets Cav1. 153, 154 . Many of the genes implicated in CNM, including MTM1 40 , DNM2 41 and 44 , encode proteins that have an important role in intricately linked intracellular membrane trafficking pathways. Mutations in these genes might indirectly affect muscle Ca 2+ handling and ECC, probably sec ondary to abnormalities of triad assembly and the ECC machinery 155 . Although such abnormalities have been demonstrated in mouse models of both DNM2related and MTM1related myopathies 156 , a recent study on MTM1mutated human myoblasts failed to demonstrate any alterations in ECC and Ca 2+ release, indicating that these alterations may reflect longterm effects in vivo 157 . The pathogenicity of TTN mutations is probably multifactorial and is likely to involve several mechan isms implicated in ECC, including calpain 3 mediated RYR1 recruitment to the triad and obscurin mediated interactions between the Ttubules, the SR and the sarcomere.
Sarcomeric abnormalities
The majority of the genes implicated in nemaline myo pathy to date, including NEB 59 , ACTA1 61 , TPM2 63 , TPM3 62 and TNNT1 68 , are involved in thin filament assembly and interactions. Pathogenic mutations in the two most commonly mutated genes, NEB and ACTA1, have been extensively studied 158 . Dominant ACTA1 mutations exert a dominantnegative effect on muscle function that is mediated through lowered Ca 2+ sensitivity, whereas recessive ACTA1 mutations abol ish functional protein expression, with the phenotype severity probably depending on the expression of com pensatory proteins such as actin, αcardiac muscle 1 (ACTC1) 159, 160 . In rare cases, ACTA1 mutations result in increased muscle contractility 161, 162 . NEB mutations affect the specific function of nebu lin in thin filament regulation and force generation 163 . The effects of various nemaline myopathyassociated mutations on the interactions of nebulin with actin and tropomyosin, thin filament length and force gen eration were demonstrated in two in vitro studies 164, 165 . MYO18B, which was found to be mutated in one family with a severe form of nemaline myopathy 75 , encodes an unconventional myosin protein with a more general role in sarcomeric assembly and maintenance 166, 167 . KBTBD13, KLHL40, KLHL41 and LMOD3, which have recently been implicated in nemaline myopathy, encode a group of Kelch and Kelchlike proteins that are not primary thin filament components but are involved in muscle quality control processes 168 and may, thus, affect myofibrillar assembly and function indirectly. Evidence for a direct interaction between Kelchlike protein 40 (KLHL40), nebulin and leiomodin 3 has been provided 169 .
The myosinopathies 99 -disorders of the thick fila ments -are likely to cause muscle disease through two principal mechanisms: disturbed thick filament inter action and function and, particularly in MYH7related congenital myopathies 99 , aggregation of abnormal protein.
Other pathogenic mechanisms
Some of the proteins implicated in congenital myo pathies are specifically involved in ECC and Ca 2+ homeo stasis, whereas others are thought to have addi tional roles in and beyond muscle. Selenoprotein N (encoded by SEPN1) belongs to a family of proteins that contain selenium in the form of the 21st amino acid, selenocysteine. In muscle, this protein has been specifically implicated in myogenesis -a role that it shares with the protein encoded by MEGF10, which is mutated in a rare form of MmD 23 -and redox regula tion 170, 171 . The important role of normally functioning redox regulation for muscle health is also illustrated by the identification of recessive mutations in the oxidoreductase encoding gene PYROXD1 as a cause of earlyonset congenital myopathies 98 .
Reflecting their essential roles in intricately linked intracellular membrane trafficking pathways, mutations in the CNMassociated genes MTM1, DNM2 and BIN1 have been associated with a wide range of downstream effects, including defects in mitochondria, the inter mediate filament protein desmin, satellite cell activation and the neuromuscular junction 155 . Abnormalities of muscle membrane systems have also been described in association with canine HACD1related CNM 86, 87 , a natu rally occurring animal model of a nonspecific congenital myopathy that has also been described in humans 172 . The CNMassociated genes MTM1 and DNM2 have also been implicated in pathways that affect muscle protein turnover and/or muscle growth and atrophy pathways. In zebrafish and mouse models of myotubu larin deficiency, disturbances of the autophagy pathway, associated with Fbox only protein 32 upregulation and atrophy, have been reported [173] [174] [175] . Abnormalities of autophagosome maturation and autophagic flux have also been described in a mouse model of DNM2-related CNM in association with marked muscle atrophy and weakness 176 . Several mechanisms might affect This membrane compartment faces the sarcoplasmic reticulum (SR) junctional face membrane (JFM), which contains ryanodine receptor 1 (RYR1) as well as junctional SR protein 1 (JP45) and the structural proteins triadin and aspartyl/asparaginyl β-hydroxylase (junctin). Calsequestrin bound to Ca 2+ forms a mesh-like structure within the lumen of the SR terminal cisternae. JP45 also interacts with calsequestrin via its lumenal carboxy-terminal domain. Ca 2+ release into the cytosol results in sarcomeric shortening through specific interactions between thin and thick filaments, in particular, the sliding of actin past myosin filaments. ECC is terminated through SR Ca 2+ reuptake through sarcoplasmic/endoplasmic reticulum Ca 2+ ATPase (SERCA) Ca 2+ pumps. SERCAs are present in the terminal cisternae as well as the longitudinal SR and are regulated by phospholamban, myoregulin and sarcolipin. The Ca ◀ autophagy and other degradation pathways in TTN related CNM. These mechanisms include abrogation of calpain 3mediated protein turnover (in the case of Cterminaltruncating TTN mutations), perturba tion of the link between titin and the ubiquitin ligase myospryn 177 , and perturbation of the link between the titin kinase domain and the autophagy cargo adap tors NBR1 (next to BRCA1 gene 1 protein NBR1) and sequestosome 1 (SQSTM1) by Mbanddisrupting TTN mutations 25 . Intriguingly, the typical histopathological features of CNM have also been reported in primary disorders of autophagy 178, 179 , further supporting a close link between defective autophagy and abnormal nuclear positioning.
A novel epigenetic mechanism involving altera tions of musclespecific microRNAs, increased DNA methy lation and increased expression of class II histone deacetylases has been reported in RYR1related myo pathies 180 and might also be relevant for other congenital myopathies 157 .
The mechanisms through which mutations in ECEL1, PIEZO2 and SCN4A cause specific earlyonset congenital myopathies are currently uncertain.
Diagnostic approach
The International Standard of Care Committee for Congenital Myopathies has provided a structured diag nostic approach to the congenital myopathies 181 . Many features, including axially pronounced weakness and hypotonia, are consistent but nonspecific on clinical assessment, whereas others -in particular, the degree of distal, extraocular muscle, cardiac and respiratory involvement -can indicate specific genetic backgrounds.
Useful laboratory investigations include measure ment of serum creatine kinase levels, which are typically normal or slightly elevated, and assays for acetylcholine receptor antibodies to exclude autoimmune myasthenic conditions 182 . Neurophysiological studies, such as elec tromyography and nerve conduction studies, are useful mainly for excluding congenital neuropathies, myotonic disorders 111 and congenital myasthenic syndromes 183 . Muscle imaging 6 , in particular, muscle ultrasonog raphy as a screening test and muscle MRI for a more detailed assessment, can reveal diagnostic patterns of selective muscle involvement. Assessment of muscle biopsy samples with a standard panel of histological, histochemical and immunohistochemical stains 13 will confirm the specific congenital myopathy and exclude distinct conditions with overlapping pathological fea tures, such as the congenital muscular dystrophies 184 , myofibrillar myopathies 185 and autophagic vacuolar myopathies 186 . Electron microscopy helps to clarify the pathognomonic structural abnormalities that are seen with light microscopy.
Concomitant analysis of multiple congenital myo pathyassociated genes through NGS is rapidly becom ing the preferred diagnostic approach. Functional studies will be increasingly relevant for pathogenicity assessment of variants in large genes such as TTN, NEB and RYR1, as variants of uncertain significance are not uncommon in these genes, even in healthy control populations.
Management and therapy development Supportive management
Supportive management (outlined in detail elsewhere 187 ) is based on a multidisciplinary approach. Regular physio therapy and provision of orthotic support is beneficial to prevent contracture development and to maintain mobility. Patients with dysarthria and/or feeding dif ficulties will benefit from regular speech and language therapy. In some cases, bulbar involvement and poor weight gain may necessitate gastrostomy. Regular mon itoring of respiratory function (including sleep studies) and proactive respiratory management (including timely noninvasive ventilation and cough assistance techniques) are essential, particularly in conditions where substan tial respiratory involvement -often disproportionate to the degree of limbgirdle weakness -is recognized. Regular cardiac monitoring is crucial for patients with congenital myopathies that are consistently associated with cardiomyopathy (in particular, the TTNrelated and MYH7related forms) and also for individuals in whom the genetic defect is uncertain. Given the oftencomplex comorbidities associated with congenital myopathies, orthopaedic surgery, most notably to treat scoliosis, should be undertaken at a tertiary neuro muscular centre. MHS must be anticipated in the anaesthetic management of patients with RYR1 or STAC3 mutations and in those with unresolved genetic backgrounds.
Mechanism-based therapies
Mechanismbased therapies for the congenital myo pathies that are already available or currently in development have been reviewed in detail elsewhere 188 .
Genetic therapies.
Owing to their enormous size, most of the genes commonly implicated in congenital myopathies are not amenable to virusbased gene transfer approaches. However, delivery of MTM1 via an adenoassociated virus 8based vector has been demonstrated to improve the clinicopathological phenotype in Mtm1deficient mice and a canine model of XLMTM 172, 189 . Restoration of the mRNA reading frame is theoret ically applicable to various congenital myopathies in which nonsense mutations are implicated. Exon skip ping has been successfully applied in vitro to remove a pseudoexon from the mRNA of a child with a recessive RYR1related myopathy 190 . Considering that carriers of truncating RYR1 mutations are asymptomatic 190, 191 , selective silencing of the mutant gene could be a fea sible therapeutic strategy for dominant RYR1related myopathies in the future. Pharmacological suppres sion of stop codons 192 by compounds such as ataluren is a potential approach in congenital myopathies that involve nonsense mutations, although it is currently uncertain whether such an approach will increase normal protein levels sufficiently to restore structural integrity and function, and the effects on the many lossoffunction variants in the human genome have yet to be determined 193 . Downregulation or upregulation of genes that act in convergent pathways could be a relevant approach for various forms of CNM. Studies have demonstrated that downregulation of dynamin 2 194 or targeting of class II and III phosphoinositide 3kinases in muscle 195 can rescue the phenotype in XLMTM animal models, suggesting that pharmacological modification of intricately linked pathways is a potential treatment modality for XLMTM and, possibly, other forms of CNM. Upregulation of cardiac actin might be a fea sible therapeutic approach for patients with ACTA1 null mutations 196, 197 .
Enzyme replacement therapy. Enzyme replacement therapy is currently relevant only to XLMTM caused by loss of myotubularin function. In Mtm1knockout mice, improvements in contractile function and histopatho logical features were observed following shortterm myotubularin enzyme replacement 198 .
Pharmacological therapies. Pharmacological therapies that are potentially applicable to congenital myopathies can be grossly divided into three principal approaches: direct modification of altered protein function (for example, modification of RYR1 release in RYR1related myopathies); enhancement of thin-thick filament inter actions (for example, in some nemaline myopathies); and therapies aimed at nonspecifically ameliorating downstream effects of the specific gene mutation.
Modification of RYR1 Ca 2+ release by use of the spe cific RYR1 antagonist dantrolene 199 is the established emergency treatment for malignant hyper thermia and has also been used effectively in a few patients with RYR1related ERM 35, 200 and CCD 201, 202 . Other compounds with the potential to treat excessive SR Ca 2+ release and/or increased SR Ca 2+ leakage are the calstabinstabilizing 1,4benzothiazepine derivatives JTV519 and S107 203, 204 and the AMPactivated protein kinase activator 5aminoimidazole4 carboxamide ribonucleotide (AICAR) 205, 206 . However, the safety pro files of these compounds in humans and their roles in RYR1related myopathies associated with reduced rather than increased Ca 2+ conductance are currently uncertain.
Enhancement of filament interactions and promo tion of force production 207, 208 , either by slowing the rate of Ca 2+ release from troponin C or by directly targeting myosin molecules, are potentially valuable approaches for some nemaline myopathies. However, concerns remain regarding fibre type specificity and potential cardiac adverse effects of the molecules that are being utilized.
Modification of the downstream effects of spe cific gene mutations encompasses various approaches. Inhibition of myostatin, an important negative regula tor of muscle fibre size 209 , might be applicable to con genital myopathies in which fibre atrophy is prominent. Following observations of increased oxidative stress and a favourable response to these compounds in animal models 154, 210, 211 , antioxidants such as Nacetylcysteine are currently being investigated in clinical trials con cerning RYR1related and SEPN1related myopathies. In light of the neuromuscular junction and transmis sion abnormalities in CNM, RYR1related MmD and KLHL40related nemaline myopathy [212] [213] [214] [215] , acetylcho linesterase inhibitors have been used with some benefit in a small number of patients. Two other compounds, salbutamol for core myopathies [216] [217] [218] and -supported by preclinical data from a relevant animal model 219 -ltyrosine in nemaline myopathy 220 , have shown apparent benefits in openlabel pilot studies.
For those disease entities where misfolded proteins or domains have unequivocal primary roles in the disease process (for example, titin in autosomal reces sive MmD with heart disease), compounds that act as chemical chaperones show promise. A pharmaco chaperone approach, using the small amphipathic com pound 4phenylbutyrate, was shown to alleviate some of the pathological features in a mouse model of PLEC associated epidermolysis bullosa simplex with muscu lar dystrophy 221 , although it is uncertain whether the observed effect was attributable to stabilization of mis folded mutant protein or its clearance through induc tion of autophagy by the drug 222, 223 . A beneficial effect of 4phenylbutyrate has also been suggested in a mouse model of RYR1related myopathy 224 . The range of chem ical chaperones is increasing rapidly 225 , but the half maximal inhibitory concentration -a measure of the ability of a compound to inhibit a specific function -is often low 226 , and the development of more targetspecific compounds might make this approach more effective and applicable.
Conclusions and outlook
Widespread clinical implementation of NGS has rapidly expanded the genetic and clinicopathological spectrum of the congenital myopathies. In addition to the classic entities CCD, MmD, CNM and nemaline myopathy, the congenital myopathies now encompass a wide range of earlyonset, nondystrophic neuromuscular dis orders with various combinations of structural defects. Congenital myopathies due to mutations in RYR1, the most common genetic cause, form a continuum with intermittent induced myopathies, such as malignant hyperthermia and exertional rhabdomyolysis, in other wise healthy individuals. Other forms of congenital myo pathy overlap substantially with the distal arthrogryposis and protein aggregation myopathy spectrum, particularly in cases where sarcomeric proteins are implicated.
The unravelling of the underlying molecular mech anisms has advanced not only our understanding of the congenital myopathies but also our knowledge of nor mal muscle physiology and homeostasis. Although the primary genetic defects and principal pathogenic mechanisms have largely been elucidated, downstream effects on muscle growth and atrophy pathways, the role of genetic and other modifiers, and the molecular basis of the common histopathological features remain uncertain.
Specific therapies for congenital myopathies, utiliz ing genetic, enzyme replacement and pharmacological approaches, are currently being developed or are already reaching the clinical trial stage, emphasizing the need for comprehensive natural history studies concerning these clinically variable conditions.
